Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

November 12, 2019

Roche’s risdiplam meets primary endpoint in phase 3 SMA trial

Roche said that part 2 of the SUNFISH trial assessing risdiplam for the treatment of Type 2 or 3 spinal muscular atrophy (SMA) in people aged 2-25 years has met its primary endpoint.

Roche’s risdiplam meets primary endpoint in phase 3 SMA trial